Claims for Patent: 9,347,073

Summary for Patent: 9,347,073

Title:	Mini-intronic plasmid vectors
Abstract:	Compositions and methods are provided for achieving persistent, high level expression of transgenes in vitro and in vivo. Aspects of the invention include vectors comprising an intronic cassette that comprises plasmid elements, and methods that rely on the use of vectors comprising an intronic cassette that comprises plasmid elements. These compositions and methods find use in many applications, including therapeutic applications such as in gene therapy; synthesis applications such as in the synthesis of peptides, proteins, and RNAs, e.g. for research or therapeutic purposes; and research applications, such as in the production of transgenic cells and animals. In addition, reagents, devices and kits thereof that find use in making the subject compositions and practicing the subject methods are provided.
Inventor(s):	Kay; Mark A. (Los Altos, CA), Lu; Jiamiao (Mountain View, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior university (Stanford, CA)
Application Number:	13/744,285
Patent Claims:	1. A mini-intronic plasmid (MIP) vector, comprising an expression cassette comprising: (a) a promoter operably linked to a transgene, (b) an intronic cassette comprising an intron, wherein the intron: (i) comprises a bacterial origin of replication and a selectable marker, (ii) is flanked by a splice donor sequence at its 5' end and a splice acceptor sequence at its 33' end, and (iii) is operably linked to said promoter, and (c) a termination sequence, wherein the MIP vector comprises less than 1 kb of nucleotide sequence external to the expression cassette and does not comprise a bacterial origin of replication or a selectable marker external to the intron. 2. The MIP vector according to claim 1, wherein the intronic cassette is 5' of the transgene. 3. The MIP vector according to claim 1, wherein the transgene comprises two or more coding exons, and the intronic cassette is flanked by two coding exons. 4. The MIP vector according to claim 1, wherein the intronic cassette is 3' of the transgene and 5' of a termination sequence. 5. The MIP vector according to claim 1, wherein the MIP vector comprises a second expression cassette, wherein the intronic cassette is comprised by the second expression cassette. 6. The MIP vector according to claim 1, wherein the MIP vector is substantially free of bacterial plasmid backbone sequences external to the intronic cassette. 7. The MIP vector according to claim 1, wherein the MIP vector is circular. 8. The MIP vector according to claim 1, wherein the MIP vector is a virus. 9. The MIP vector according to claim 8, wherein the virus is an adenovirus. 10. An isolated nucleic acid, comprising: an intronic cassette comprising an intron, wherein the intron: (i) comprises a bacterial origin of replication and a selectable marker, and (ii) is flanked by a splice donor sequence at its 5' end and a splice acceptor sequence at its 3' end. 11. The nucleic acid according to claim 10, wherein the intronic cassette comprises a 5' exonic splicing enhancer (5' ESE). 12. The nucleic acid according to claim 10, wherein the intronic cassette comprises a 3' exonic splicing enhancer (3' ESE). 13. The nucleic acid according to claim 10, wherein the intronic cassette comprises a G triplet sequence. 14. The nucleic acid according to claim 10, wherein the intronic cassette comprises a polypyrimidine tract. 15. The nucleic acid according to claim 10, wherein the intronic cassette comprises a consensus branch point sequence (BPS). 16. The nucleic acid according to claim 10, further comprising a promoter operably linked to the intronic cassette. 17. The nucleic acid according to claim 10, wherein the nucleic acid is substantially free of bacterial plasmid backbone sequences other than those in the intronic cassette. 18. A method of expressing a transgene in a cell, the method comprising: introducing into a cell a mini-intronic plasmid (MIP) vector comprising an expression cassette comprising: (a) a promoter operably linked to the transgene, (b) an intronic cassette comprising an intron, wherein the intron: (i) comprises a bacterial origin of replication and a selectable marker, filis flanked by a splice donor sequence at its 5' end and a splice acceptor sequence at its 3' end, and (iii) is operably linked to said promoter, and (c) a termination sequence, wherein the MIP vector comprises less than 1 kb of nucleotide sequence external to the expression cassette and does not comprise a bacterial origin of replication or a selectable marker external to the intron. 19. The method according to claim 18, wherein the introducing occurs in vitro. 20. The method according to claim 18, wherein the introducing occurs in vivo. 21. The method according to claim 18, wherein the cell is a mammalian cell. 22. The MIP vector according to claim 1, wherein the MIP vector is a plasmid. 23. The method according to claim 18, wherein the MIP vector is a Plasmid. 24. The nucleic acid according to claim 10, wherein said nucleic acid does not comprise a bacterial origin of replication or a selectable marker external to the intron. 25. A mini-intronic plasmid (MIP) vector, comprising an expression cassette comprising: (a) a promoter operably linked to a transgene, (b) an intronic cassette comprising an intron, wherein the intron: (i) comprises a bacterial origin of replication and a selectable marker, Qpis flanked by a splice donor sequence at its 5' end and a splice acceptor sequence at its 3' end, and (iii) is operably linked to said promoter, and (c) a termination sequence, wherein the MIP vector does not comprise a bacterial origin of replication or a selectable marker external to the intron, and wherein the MIP vector is a plasmid and the plasmid backbone comprises less than 1 kb nucleotide sequence. 26. The MIP vector according to claim 25, wherein the intronic cassette is 5' of the transgene. 27. The method according to claim 18, wherein the MIP vector is circular. 28. The method according to claim 18, wherein the intronic cassette is 5' of the transgene. 29. The method according to claim 18, wherein the MIP vector is substantially free of bacterial plasmid backbone sequences external to the intronic cassette. 30. The MIP vector according to claim 25, wherein the MIP vector is substantially free of bacterial plasmid backbone sequences external to the intronic cassette.

Details for Patent 9,347,073

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2032-02-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2032-02-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2032-02-10